deListed Australia
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


ASX, Legal & CGT Status


(updated at weekends)
Former (or subsequent) names


Shareholder links
Our website ranking of ALT: rating 3
(3 out of 5)


Link Market Services Brisbane
Level 21, 10 Eagle Street Brisbane QLD 4000
Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details
ISIN: AU000000ALT0
Address: c/- Avance Chartered Accountants 222 Bazaar Street Maryborough Queensland 4650
Tel:  07 3278 1950 Fax: (07) 4122 3924

Date first listed: 25/10/2000
Company Secretary: Bryan Dulhunty

Sector: Health Care Equipment & Services
Industry Group: XHJ
Activities: Development and supply of medical devices for the healthcare workplace

liquidator appointed


delisted for non-payment of annual listing fee under Listing Rule 17.15


we understand the entity failed to pay the annual listing fee


Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Monday, 21 August 2023 would have its securities suspended from Official Quotation before the commencement of trading on Tuesday, 22 August 2023. The following entity has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2024 and consequently will have its securities suspended from quotation immediately. The company has failed to pay to ASX the annual listing fees for the year ending 30 June 2024, and its securities are already suspended from quotation.


Shareholders in this company should consider crystallising a capital loss in 2023/24 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.


A second meeting of creditors was held on 20 July 2023 where creditors approved a DOCA proposed by Stratos MedTech and Stratos MedTech Holdings. The DOCA was entered into 24 July 2023. Analytica has entered into and completed the asset sale agreement in accordance with the DOCA under which the Stratos Companies agreed to buy and Analytica agreed to sell its business and assets and shares in Pericoach and Invion. The assets and shares were sold on an 'as is where is' basis with no warranties. The Directors now presently intend to seek shareholders' approval for the delisting and winding up of Analytica by a solvent liquidation following completion of the DOCA, which is expected within approximately 2 months.


The company releases a notification of cessation of securities.


The company's voluntary administrators, David Clout and Scott Clout of David Clout & Associates, will seek urgent Expressions of Interest for the sale and/or recapitalisation of the business and/or assets of Analytica. EOIs should be submitted to the Administrators by 5.00pm AEST on 4 July 2023. Further information will be made available to interested parties on request from David Clout & Associates, subject to execution of a suitable confidentiality agreement. The Administrators intend to issue a report to creditors by no later than 10 July 2023 and convene a second meeting of creditors, pursuant to Section 439A of the Corporations Act 2001, to be held on or about 17 July 2023.


Scott Clout and David Clout have been appointed as Joint and Several Administrators of the Company.


The final date for exercising the Company's listed options (ASX Code: ALTOB is 5.00pm (AEDT) on 18TH June 2023. The exercise price is A$0.005 cents per Option and for every Option exercised, the Option holder will be issued with one Ordinary Share in Analytica. Options not exercised by 18th June 2023 will automatically lapse and will no longer be available for exercise. Quotation of the options on the ASX will cease on 12 June 2023 (being 5 business days prior to expiry).


The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.


The company issues a response to ASX Query.


The entity's securities will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Wednesday, 1 March 2023, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office yesterday and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.


The company lodges its unaudited Appendix 4D and financial report.


The expiring options of Analytica Limited will be suspended from quotation immediately today, Monday 26 February 2018 pending expiry and removal from official quotation. The Company's fully paid ordinary securities are not affected by this suspension.


The suspension of trading in the securities of Analytica Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the proposed capital raising. Security Code: ALT


Analytica Limited (Company) requests that ASX extends the voluntary suspension of the trading in its securities.


The securities of Analytica Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a proposed capital raising. Security Code: ALT


we understand that on or about this date the company consolidated its shares 1 for 10



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates
Post your comments here
Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    18/12/2014Michael MonsourOn market282,000$0.030$7,365
    16/12/2014Michael MonsourOn market65,000$0.027$1,727
    31/03/2014Michael MonsourOn market100,000$0.027$2,700
    11/03/2014Michael MonsourOn market821,000$0.026$21,346
    11/03/2014Ross MangelsdorfOn market450,000$0.026$11,700

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    Michael MonsourExecutive Chairman28/06/2004
    Bryan DulhuntyCFO12/03/2014
    Peter CorrNon Exec Director23/05/2017
    Ross MangelsdorfExecutive Director07/10/2008

    Date of first appointment, title may have changed.

    Directors & Executives (former)
    Geoff DalyCEO12/02/201412/05/2023
    Thomas LonngrenNon Exec Director10/08/201518/08/2020
    Carl StubbingsNon Exec Director13/01/201430/11/2017
    Warren BrooksDirector25/07/201130/11/2017
    David GoochNon Exec Director30/11/200425/07/2011
    Stephen JonesNon Exec Chairman03/12/200130/04/2010
    Jim HeckathornNon Exec Director21/07/2009
    Julie NuttingNon Exec Director30/06/2006
    Stephen GoodallManaging Director12/11/200420/01/2006

    Date of first appointment, title may have changed.